| 54 Saccharomyces cerevisiae is engineered to produce high concentrations of artemisinic acid, a precursor of the artemisinin used in combination therapies for malaria treatment; an efficient and practical chemical process to convert artemisinic acid to artemisinin is also developed.
53 Enantioselective Synthesis of Pactamycin, a Complex Antitumor Antibiotic.
52 A Yeast Chemical Genetic Screen Identifies Inhibitors of Human Telomerase.
51 Piperazine and Piperidine Triazole Ureas as Ultrapotent and Highly Selective Inhibitors of Monoacylglycerol Lipase.
50 Identification of a Broad-Spectrum Inhibitor of Viral RNA Synthesis: Validation of a Prototype Virus-Based Approach.
49 Quinolone-3-Diarylethers: A New Class of Antimalarial Drug.
48 Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo.
47 Biomimetic enzyme nanocomplexes and their use as antidotes and preventive measures for alcohol intoxication.
46 ATP-directed capture of bioactive herbal-based medicine on human tRNA synthetase.
45 Antibacterial drug leads targeting isoprenoid biosynthesis.
44 Automated design of ligands to polypharmacological profiles.
43 Treating Diabetes and Obesity with an FGF21-Mimetic Antibody Activating the βKlotho/FGFR1c Receptor Complex.
42 Lithographically Encoded Polymer Microtaggant Using High-Capacity and Error-Correctable QR Code for Anti-Counterfeiting of Drugs.
41 CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson's disease.
40 PEG-b-PtBA-b-PHEMA well-defined amphiphilic triblock copolymer: Synthesis, self-assembly, and application in drug delivery.
39 Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain.
38 A Papaver somniferum 10-Gene Cluster for Synthesis of the Anticancer Alkaloid Noscapine.
37 Large-scale prediction and testing of drug activity on side-effect targets.
36 Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.
35 Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts.